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The interindividual and intraindividual variabilities in daptomycin pharmacokinetics were investigated in 23 patients (69 phar-
macokinetic profiles) who were treated for several months for bone and joint infections. Population daptomycin clearance was
significantly influenced by renal function and was significantly higher in male than in female patients. We observed significant
intraindividual changes in daptomycin clearance, which were uncorrelated with changes in renal function, suggesting that thera-
peutic drug monitoring is important in patients receiving prolonged daptomycin therapy.
Daptomycin is a cyclic lipopeptide that has been proposed as analternative therapeutic option in patients with prosthetic
joint infection caused by Staphylococcus or Enterococcus species in
the latest Infectious Diseases Society of America (IDSA) guide-
lines (1).
The population pharmacokinetics (PK) of daptomycin have
been described in various groups of patients in previous publica-
tions (2–5). However, little information exists on the PK of dap-
tomycin in patients with bone and joint infections (BJI). Also,
previous population studies did not investigate daptomycin PK
over prolonged therapy, and, to our knowledge, no study has re-
ported the intraindividual PK variability of this drug.
(This work was presented in part at the 54th ICAAC Meeting,
Washington, DC, 5 to 9 September 2014, and at the 34th RICAI
meeting, Paris, France, 13 to 15 December 2014.)
We performed a retrospective analysis of PK data collected in
23 patients who were treated with daptomycin for BJI in Lyon
Center in 2012 and 2013. Therapeutic drug monitoring (TDM) of
daptomycin was performed regularly in those patients throughout
therapy, roughly every month, to ensure sufficient exposure and
to prevent drug accumulation. This project was reviewed by our
local institutional review board (CPP Sud-Est III), and a waiver
was obtained, as this was a noninterventional study.
On each TDM occasion, a daptomycin PK profile was obtained
based on three concentrations usually measured at predose
(trough level), 0.5 to 1 h, and 5 to 6 h postdose. A total of 203
daptomycin plasma concentrations and 69 individual PK profiles
were determined for the 23 individuals. The exact daptomycin
doses, dosing times, dose intervals, blood sampling times, and
plasma concentrations were recorded for each subject on each
occasion. All patients received daptomycin as a 30-min infusion.
The dose interval was 24 h, except for 6 profiles from 4 patients in
whom it was 48 h because of renal impairment. Other data avail-
able on each occasion included age, sex, height, weight, serum
creatinine, estimated glomerular filtration rate (eGFR) provided
by the 4-variable modification of diet in renal disease (MDRD)
equation (6), and concomitant use of rifampin (10 profiles from 3
patients).
Daptomycin concentrations were determined by using a high-
performance liquid chromatography assay with a photodiode ar-
ray detector. Concentrations were calculated at two wavelengths
(260 and 360 nm), and a spectral analysis was performed to ensure
chromatographic peaks purity. Accuracy and precision were eval-
uated at three levels (2.5, 35, and 80 mg/liter). The interday pre-
cision was less than 11% with a bias lower than 8%. The lower
limit of quantification was 2 mg/liter.
A population approach was used to analyze the PK data. Non-
linear mixed-effects modeling was performed using the stochastic
approximation expectation maximization (SAEM) algorithm im-
plemented in the Monolix software (version 4.3.3; Lixoft, Paris,
France). Selection of the best structural and covariate model was
based on classical criteria, including the likelihood-derived objec-
tive function, parameter estimates, predictive performance, and
diagnostic plots (7, 8). We assumed log normal distribution of PK
parameters. The special feature of this analysis was the inclusion of
intraindividual variability, which was implemented by using the
interoccasion variability (IOV) routine of Monolix. The interin-
dividual and intraindividual variabilities of PK parameters were
coded in Monolix as follows:
Pik  Cik  exp i  exp ik (1)
where Pik is the parameter value of individual i on occasion k, Cik
is the matrix of covariates of individual i on occasion k,  is the
mean population parameter value (fixed effect), and i and ik are
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the interindividual and intraindividual variability terms, respec-
tively. Those random effects, i and ik, were assumed to follow
normal distributions: i  N(0, ) and ik  N(0, ).
Intraindividual variability was set on clearance and volume of
distribution parameters only. As a result, for each subject, a value
of daptomycin clearance (CL) and central volume of distribution
(V1) were estimated for each TDM occasion. Finally, we studied
the correlation between individual, chronological changes in pa-
rameter values from one TDM occasion to the next one and the
corresponding changes in covariates.
The characteristics of the study population are shown in Table
1. A daptomycin PK profile was obtained on at least two occasions,
except for six patients, with a median of three profiles per patient.
A two-compartment linear PK model, including a propor-
tional residual error, best fit the data. The introduction of intra-
individual variability into the model greatly improved the fit (50-
point decrease in the Akaike information criterion [AIC])
compared with that of a two-compartment model with interindi-
vidual variability only. The final model, including covariates, ad-
equately described the data as shown in Fig. 1. Parameter values of
the final model are shown in Table 2. Regarding covariates, sex was
found to influence population daptomycin CL and V1, which were
44% (0.81 versus 0.564 liters/h) and 30% (11 versus 8.43 liters)
greater in male than in female patients, respectively. Although this
needs to be confirmed in a larger study, this finding suggests that
male patients may need larger doses of daptomycin in order to
achieve a target exposure. Of note, body weight did not appear to
significantly influence daptomycin clearance or its volume of dis-
tribution in this population. In addition, renal function, as esti-
mated by MDRD-eGFR, was also found to significantly influence
population daptomycin CL. A moderate but significant linear cor-
relation was observed between individual estimates of daptomy-
cin CL and eGFR values (R2  0.27, data not shown). However,
individual chronological changes in daptomycin CL over the
TDM period, which ranged from 	60% to 
185%, were uncor-
related with corresponding changes in renal function as shown in
Fig. 2. Figure 3 shows intraindividual changes in daptomycin area
under the concentration-time curve (AUC) during therapy. Despite
the administration of the same daily dose, the AUC varied substan-
tially in some patients as a result of changes in daptomycin CL.
The PK model, population parameter values, and covariates
identified in this study are consistent with previous reports (2, 4,
5). In particular, our study and previous works have found that
daptomycin clearance correlates with renal function, which is in
agreement with the predominant renal excretion of the drug (9).
As a result, one might assume that renal function can be used as
guidance for initial dosing and dose adjustment during daptomy-
cin therapy.
In that study, we found substantial intraindividual variability
in daptomycin PK in a group of patients with prolonged dapto-
mycin administration for BJI. Importantly, such variability was
FIG 1 Plots of observed daptomycin concentrations (n  203) versus model-
based population (circles and dotted line) and individual (black diamond and
solid line) predictions. The dashed line is the line of identity (y  x).
TABLE 2 Population pharmacokinetic parameters of daptomycin
Parametera,b
Mean value
(relative SE)c
Interindividual
variability (%)c
Intraindividual
variability (%)c
CL (liter/h) 0.564 (6%) 5.3 22.5
1(CL, eGFR) 0.00307 (24%) ND
d ND
2(CL, sex) 0.362 (20%) ND ND
V1 (liters) 8.43 (9%) 4.2 24.6
3(V1, sex) 0.265 (38%) ND ND
Q (liters/h) 0.596 (41%) 71.2 ND
V2 (liters) 7.17 (40%) 59.7 ND
a CL, daptomycin plasma clearance; Q, intercompartment clearance; V1, central volume
of distribution; V2, volume of the peripheral compartment.
b Coefficients  quantify the relationships between population parameters (CLpop,
V1pop) and covariates as follows: CLpop  0.564 · exp[1 · (eGFR/108) 
 2 (if
male)], where 108 is the median value of eGFR in the study population (ml/min/1.73
m2) and V1pop  8.43[exp(3) if male].
c Relative standard error and interindividual and intraindividual variability are
expressed as coefficient of variation (%).
d ND, not determined.
TABLE 1 Characteristics of the study population and pharmacokinetic
data set
Characteristic Valuea
Age (yr) 68 (19–84)
No. of females/males 9/14
Initial body wt (kg) 72 (47–140)
Initial renal function (eGFR in ml/min/1.73
m2, MDRD equation)
118 (24–202)
Daptomycin dose (mg/kg) 8 (3–11)
Duration of daptomycin TDM (days) 110 (8–247)
No. of TDM occasions per subject 3 (1–7)
No. of measured daptomycin concentrations 203
Measured daptomycin concn (mg/liter)b C0  13.4 (2.9–50.6)
C30 min  59.7 (21.8–104.1)
C5–6 h  38.8 (17–70.6)
Estimated daptomycin AUC0–24 (mg · h/liter)
c 683.2 (305.6–1471.1)
a Except where indicated by No., data are given as medians (minimum to maximum).
b C0, C30 min, and C5– 6 h indicate the daptomycin concentrations measured predose
(trough concentration), 30 min, and 5 to 6 h postdose, respectively.
c AUC0 –24 is the individual steady-state AUC calculated over 24 h using the final PK
model.
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not predictable from corresponding time changes in renal func-
tion. Actually, this variability has remained unexplained. These
results suggest that renal function has basically no guidance value
for adjusting daptomycin dosing during individual therapy.
The main limitation of this study was the limited number of
patients included (n  23). This probably affected the estimation
of the interindividual variability, which was surprisingly low for
CL and V1, about 5%, while previous studies reported coefficients
of variations of 20% to 40% (2, 4). It is noteworthy that these
numbers reflect the interindividual variability that is unexplained
by covariates, not the overall interindividual variability in CL and
V1, which was larger (about 31% for CL and 19% for V1 based on
individual estimates on the first TDM occasion). However, this
limitation had no influence on the estimation of the mean values
and intraindividual variability of PK parameters, and it did not
undermine the predictive performance of the model. On the other
hand, interindividual variability may well have been overesti-
mated in previous studies, which ignored interoccasion variability
as shown in the seminal work of Karlsson and Sheiner (10).
To conclude, this study has shown the significant intraindi-
vidual PK variability of daptomycin during long-term use for
treatment of BJI, and this variability was unexplained by covari-
ates. Daptomycin TDM appears necessary to control individual
exposure and to adjust drug dosage during prolonged therapy.
Experimental data have suggested daptomycin maximum con-
centration of drug in serum (Cmax) and area under the concentra-
tion-time curve from 0 to 24 h (AUC0 –24) values of 30 to 46 g/ml
and 294 to 375 g · h/ml, respectively, to achieve a bactericidal
activity against Staphylococcus aureus (11). In addition, a clinical
study identified that a daptomycin plasma concentration of 24.3
mg/liter was associated with a significant increase in daptomycin
muscular toxicity (12). While little information exists on dapto-
mycin PK/pharmacodynamics (PD) in BJI, Traunmüller et al. ob-
served a similar free concentration of daptomycin in bone and
plasma (13). Based on these data, and although further research is
necessary, a daptomycin peak of 50 g/ml and trough of 24
g/ml may be considered target concentrations for TDM of dap-
tomycin in BJI.
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